

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

GENENTECH, INC. and CITY OF HOPE,

Plaintiffs,

v.

AMGEN INC.,

Defendant and Counterclaim  
Plaintiff.

Case No. 1:18-cv-00924-CFC

PUBLIC VERSION

**AMGEN'S COMBINED OPPOSITION TO GENENTECH'S EMERGENCY MOTIONS  
FOR A TEMPORARY RESTRAINING ORDER AND A PRELIMINARY INJUNCTION**

*Of Counsel:*

Michelle Rhyu  
Susan Krumplitsch  
Daniel Knauss  
COOLEY, LLP  
3175 Hanover Street  
Palo Alto, CA 94304-1130  
P 650-843-5287  
rhyums@cooley.com  
skrumplitsch@cooley.com  
dknauss@cooley.com

Eamonn Gardner  
COOLEY, LLP  
4401 Eastgate Mall  
San Diego, CA 92121-1909  
P 858-550-6086  
egardner@cooley.com

Orion Armon  
COOLEY, LLP  
380 Interlocken Crescent  
Suite 900  
Broomfield, CO 80021-8023  
P 720-566-4119  
oarmon@cooley.com

Neal Belgam (No. 2721)  
Eve H. Ormerod (No. 5369)  
SMITH, KATZENSTEIN & JENKINS LLP  
1000 West Street, Suite 1501  
Wilmington, DE 19801  
P 302-652-8400  
nbelgam@skjlaw.com  
eormerod@skjlaw.com

*Attorneys for Defendant Amgen Inc.*

Nancy Gettel  
Brian Kao  
Lois M. Kwasigroch  
AMGEN, INC.  
One Amgen Center Drive  
Thousand Oaks, CA 91320-1799  
P 805-447-1000  
ngettel@amgen.com

## TABLE OF CONTENTS

	<b>Page</b>
INTRODUCTION .....	1
LEGAL STANDARD.....	2
BACKGROUND .....	3
A.    THE PATENTS .....	3
B.    THE INTER PARTES REVIEW (IPR) PROCEEDINGS AT THE U.S. PATENT OFFICE.....	5
C.    GENENTECH’S KNOWLEDGE OF AMGEN’S LAUNCH PLANS.....	6
D.    GENENTECH’S LICENSES .....	8
ARGUMENT.....	8
I.    INJUNCTIVE RELIEF IS UNWARRANTED IN LIGHT OF GENENTECH’S INTENTIONAL DELAY IN SEEKING RELIEF .....	8
II.   GENENTECH WILL NOT EXPERIENCE IRREPARABLE HARM.....	10
A.    Genentech’s delay in seeking a TRO and PI belies its assertion that it will be irreparably injured absent such relief.....	10
B.    Genentech’s willingness to grant [REDACTED] licenses to the asserted patents shows that harm (if any) from sales of Kanjinti is calculable and not irreparable .....	10
C.    Genentech employee admissions confirm that it will not experience irreparable harm from Amgen’s commercial marketing of Kanjinti .....	11
D.    [REDACTED] .....	12
E.    During the period between now and trial, Genentech estimates [REDACTED] .....	13
III.  GENENTECH HAS NOT SHOWN A LIKELIHOOD THAT IT WILL SUCCEED ON THE MERITS .....	14
A.    Amgen does not infringe any valid claims .....	14
B.    The Dosing Patents are invalid as obvious .....	14
1.    Amgen does not rely on the same prior art as the previous IPRs .....	15

**TABLE OF CONTENTS**  
**(continued)**

	<b>Page</b>
2. The PTAB’s decision turned on Petitioners’ failure to establish a reasonable expectation of success of the obvious combination.....	16
3. Amgen’s evidence demonstrates reasonable expectation of success of the obvious claim steps.....	16
IV. THE BALANCE OF HARDSHIPS FAVORS DENYING GENENTECH’S MOTIONS .....	19
V. DENYING GENENTECH’S MOTIONS WOULD PROMOTE THE PUBLIC INTEREST .....	20
VI. CONCLUSION.....	20

**TABLE OF AUTHORITIES**

	<b>Page(s)</b>
<b>Cases</b>	
<i>Amazon.com, Inc. v. Barnesandnoble.com, Inc.</i> , 239 F.3d 1343 (Fed. Cir. 2001).....	3
<i>Anjelino v. New York Times Co.</i> , 200 F.3d 73 (3d Cir. 1999).....	10
<i>Apple Inc. v. Samsung Elecs. Co. Ltd.</i> , 735 F.3d 1352 (Fed. Cir. 2013).....	20
<i>AstraZeneca LP v. Apotex, Inc.</i> , 633 F.3d 1042 (Fed. Cir. 2010).....	3
<i>Baxalta Inc. v. Genentech, Inc.</i> , No. 17-509-TBD, 2018 WL 3742610 (D. Del. Aug. 7, 2018).....	12
<i>BMEF San Diego, L.L.C. v. Gray E. Vill. San Diego L.L.C.</i> , No. No. 9963–VCN, 2014 WL 4923722 (Del. Ch. Sept. 30, 2014).....	8
<i>Cordance Corp. v. Amazon.com, Inc.</i> , No. 06–491–MPT, 2010 WL 3155505 (D. Del. July 23, 2010).....	11
<i>Cordis Corp. v. Boston Sci. Corp.</i> , No. Civ.A. 03–027–SLR, 2003 WL 22843072 (D. Del. Nov. 21, 2003), <i>aff’d</i> , 99 F. App’x 928 (Fed. Cir. 2004) .....	10, 13
<i>In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litig.</i> , No. 09–MD–2118–SLR, 2011 WL 1980610 (D. Del. May 20, 2011).....	2
<i>eBay Inc. v. MercExchange, L.L.C.</i> , 547 U.S. 388 (2006).....	2
<i>In re Gen. Motors (Hughes) S’holders Litig.</i> , No. 20269-NC, 2003 WL 26474920 (Del. Ch. Oct. 2, 2003).....	10
<i>Graceway Pharm., LLC v. Perrigo Co.</i> , 722 F. Supp. 2d 566 (D.N.J. 2010).....	9, 20
<i>Immunomedics, Inc. v. Venbio Select Advisor LLC</i> , No. 17-176-LPS, 2017 WL 822800 (D. Del. Mar. 2, 2017).....	3, 8, 10
<i>Intirtoll, Ltd. v. Texar Corp.</i> , 369 F.3d 1289 (Fed. Cir. 2004).....	9

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.